Table 1 Patient characteristics
Characteristics | With PET/CT N = 132 (%) | Without PET/CT N = 319 (%) |
|---|---|---|
Age (years) | ||
< 45 | 65 (49.2%) | 169 (53.0%) |
≥ 45 | 67 (50.8%) | 150 (47.0%) |
Sex | ||
Male | 106 (80.3%) | 238 (74.6%) |
Female | 26 (19.7%) | 81 (25.4%) |
rEBV DNA (copies/ml) | ||
Undetectable | 48 (36.4%) | 105 (32.9%) |
Detectable | 69 (52.3%) | 167 (52.4%) |
Unkown | 15 (11.4%) | 47 (14.7%) |
rLactate dehydrogenase (U/L) | ||
< 240 | 117 (88.6%) | 247 (77.4%) |
≥ 240 | 5 (3.8%) | 7 (2.2%) |
Unkown | 10 (7.6%) | 65 (20.4%) |
rC-reactive protein (mg/L) | ||
< 10.5 | 107 (81.1%) | 218 (68.3%) |
≥ 10.5 | 18 (13.6%) | 30 (9.4%) |
Unkown | 7 (5.3%) | 71 (22.3%) |
rAlbumin (g/L) | ||
<39.4 | 4 (3.0%) | 30 (9.4%) |
≥ 39.4 | 121 (91.7%) | 224 (70.2%) |
Unkown | 7 (5.3%) | 65 (20.4%) |
rNLR | ||
< 3.7 | 89 (67.4%) | 189 (59.2%) |
≥ 3.7 | 41 (31.1%) | 108 (33.9%) |
Unkown | 2 (1.5%) | 22 (6.9%) |
rT category* | ||
rT0-rT2 | 91 (68.9%) | 228 (71.5%) |
rT3-rT4 | 41 (31.1%) | 91 (28.5%) |
rN category* | ||
rN0 | 80 (60.6%) | 159 (49.8%) |
rN1-rN3 | 52 (39.4%) | 160 (50.2%) |
rStage* | ||
r0-rII | 78 (59.1%) | 199 (62.4%) |
rIII-rIVA | 54 (40.9%) | 120 (37.6%) |
Intial stage | ||
I-II | 23 (17.4%) | 51 (16.0%) |
III-IVA | 109 (82.6%) | 268 (84.0%) |
Pathological examination sites | ||
Primary tumor | 79 (59.8%) | 172 (53.9%) |
Regional lymph nodes | 50 (37.9%) | 138 (43.3%) |
Both | 3 (2.3%) | 9 (2.8%) |
Treatment | ||
Salvage Surgery | 60 (45.5%) | 160 (50.2%) |
Re-radiotherapy | 48 (36.4%) | 84 (26.3%) |
Palliative treatment | 24 (18.2%) | 75 (23.5%) |